SCHEMBL3672992

SCHEMBL3672992

COC(=O)c1cc2c(cc1C(=O)OC)C(=O)N(OC(C)=O)C2=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.40
GABRA1 P14867 2/20 0.39
GABRG2 P18507 2/20 0.39
GABRB3 P28472 2/20 0.39
GABRA3 P34903 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
ALDH1A1 P00352 2/20 0.38
ATM Q13315 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA7 P43166 2/20 0.36
CA9 Q16790 2/20 0.36
CA14 Q9ULX7 2/20 0.36
PDK2 Q15119 1/20 0.36
PDK4 Q16654 1/20 0.36
CASP3 P42574 1/20 0.36
KDM4E B2RXH2 4/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3678764 0.82 GABRA1 (0.31) GABRA1GABRG2GABRB3GABRA3GABRA5
SCHEMBL3675236 0.82 GAA (0.47) MAPTSMN1; SMN2ALDH1A1ATMCA12
SCHEMBL3678655 0.82 CA12 (0.41) MAPTALDH1A1CA12CA1CA2
SCHEMBL3684899 0.81 ALDH1A1 (0.56) SMN1; SMN2ALDH1A1ATMNPSR1CA12
SCHEMBL3677491 0.80 ALDH1A1 (0.46) ALDH1A1KDM4ELMNATSHRHSD17B10
SCHEMBL3678858 0.79 HSD17B10 (0.44) MAPTSMN1; SMN2ALDH1A1NPSR1KDM4E
SCHEMBL3682116 0.79 ALDH1A1 (0.47) MAPTSMN1; SMN2ALDH1A1ATMNPSR1
SCHEMBL2240268 0.78 GABRA1 (0.43) MAPTGABRA1GABRG2GABRB3GABRA3
SCHEMBL3684385 0.77 NPC1 (0.42) MAPTSMN1; SMN2ALDH1A1ATMNPSR1
SCHEMBL3684358 0.77 NPC1 (0.42) MAPTSMN1; SMN2ALDH1A1ATMNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741514-B2 Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2010-06-22 US disclosed
US-20060281629-A1 Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst ISHII YASUTAKA 2006-12-14 US disclosed
US-7115541-B2 Catalyst comprising n-substituted cyclic imides and processes for preparing organic compounds with the catalyst DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2006-10-03 US disclosed
EP-1338336-A1 CATALYSTS COMPRISING N-SUBSTITUTED CYCLIC IMIDES AND PROCESSES FOR PREPARING ORGANIC COMPOUNDS WITH THE CATALYSTS Daicel Chemical Industries, Ltd. (JP) 2003-08-27 EP disclosed
US-20030013603-A1 Catalyst comprising n-substituted cylic imides and processes for preparing organic compounds with the catalyst DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2003-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281629-A1 Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst NOS2, NOS1, NOS3 MAPT 4792/4885GABRA1 334/4885GABRG2 635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.